If a woman has not had a thrombotic event in years of use she is unlikely to have one nowBMJ 1995; 311 doi: https://doi.org/10.1136/bmj.311.7020.1638c (Published 16 December 1995) Cite this as: BMJ 1995;311:1638
- John Guillebaud
- Professor of family planning and reproductive health Margaret Pyke Family Planning Centre, London W1P 1LB
EDITOR,--My editorial commenting on the letter from the Committee on Safety of Medicines and the three studies that gave rise to it had to be cut because of lack of space.1 In the original version I argued that, in these trials, the proportion of women who had been exposed in the past to ethinyloestradiol (in any combination) might be higher among current users of the third generation pills containing desogestrel and gestodene; ethinyloestradiol is still recognised as the prime prothrombotic constituent of …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial